Skip to content
AirNexis Therapeutics
  • Approach
  • About
  • News
  • Careers
Contact

  • AirNexis Announces that AN01 Met its Primary Endpoint in a Phase 2b COPD Study

    AirNexis Therapeutics announces that AN01 conducted in China by AirNexis’ partner Haisco Pharmaceutical Group

  • AirNexis Launches with $200 Million Series A to Advance AN01

    AirNexis acquires exclusive rights to develop AN01 outside of China from Haisco Pharmaceutical Group

AirNexis Therapeutics
  • Home
  • Approach
  • About Us
  • News
  • Careers
  • Contact
AirNexis on LinkedIn

© 2026 AirNexis Therapeutics. All rights reserved.

  • Privacy Policy
Manage Consent
We use cookies to understand how you use this site and to improve your experience.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
Preferences
  • {title}
  • {title}
  • {title}